Work

Biomarkers in a phase 1b study of investigational microbiome therapeutic SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT).

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.6554

Authors: Doris M. Ponce, Swarna Pandian, Marcel R. M. van den Brink, Satyajit Kosuri, Nandita Khera, Zachariah Michael DeFilipp, Bindu Tejura, David I Lichter, Meghan Chafee, Kankana Bardhan, Nathan D Hicks, Emily Walsh, Mary-Jane Lombardo, Christopher B. Ford, Lisa von Moltke, Matthew R. Henn, Jonathan U. Peled, Seres Therapeutics SER-155 Team

Institutions: Memorial Sloan Kettering Cancer Center, Seres Therapeutics (United States), University of Chicago, Mayo Clinic, Mayo Clinic Hospital, Massachusetts General Hospital

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Seres Therapeutics

OpenAlex ID: W4399520051

Cites:

Cited by:

Related to: 10